Inhibikase Therapeutics, Inc. (IKT)
NASDAQ: IKT · Real-Time Price · USD
1.900
-0.080 (-4.04%)
Apr 17, 2025, 4:00 PM EDT - Market closed
Inhibikase Therapeutics Employees
As of December 31, 2024, Inhibikase Therapeutics had 16 total employees, including 15 full-time and 1 part-time employees. The number of employees increased by 7 or 77.78% compared to the previous year.
Employees
16
Change (1Y)
7
Growth (1Y)
77.78%
Revenue / Employee
n/a
Profits / Employee
-$1,719,993
Market Cap
141.25M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 16 | 7 | 77.78% |
| Dec 31, 2023 | 9 | 2 | 28.57% |
| Dec 31, 2022 | 7 | 0 | - |
| Dec 31, 2021 | 7 | 4 | 133.33% |
| Dec 31, 2020 | 3 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novartis AG | 75,883 |
IKT News
- 5 days ago - Inhibikase Therapeutics Announces Appointment of David McIntyre as Chief Financial Officer - GlobeNewsWire
- 22 days ago - Inhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent Activity - GlobeNewsWire
- 7 weeks ago - Inhibikase Announces Expansion of Senior Leadership Team - GlobeNewsWire
- 2 months ago - Inhibikase Appoints Industry Veteran Mark Iwicki as CEO to Drive Next Stage of Company's Growth - GlobeNewsWire
- 2 months ago - Inhibikase Therapeutics stops Parkinson's drug development as it fails to show benefits in study - Reuters
- 5 months ago - Inhibikase: Potential To Improve Current Treatment Options For PAH Patients - Seeking Alpha
- 5 months ago - Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Activity - GlobeNewsWire
- 6 months ago - Inhibikase Therapeutics Announces Closing of up to $275 Million Financing and Advancement of IkT-001Pro into a Late Stage Clinical Trial in Pulmonary Arterial Hypertension - GlobeNewsWire